Cart
sales@molnova.com
RBC8
CAS No. 361185-42-4
RBC8( RBC8 | RBC-8 | RBC 8 )
Catalog No. M17494 CAS No. 361185-42-4
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 150 | In Stock |
|
| 25MG | 297 | In Stock |
|
| 50MG | 461 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | 918 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRBC8
-
NoteResearch use only, not for human use.
-
Brief DescriptionRBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
-
DescriptionRBC8 is a RalA and RalB GTPase inhibitor (EC50 ~3.5 μM). RBC8 suppresses growth of xenograft tumors in mice. e Ras-like GTPases RalA and RalB are important drivers of tumour growth and metastasis. Chemicals that block Ral function would be valuable as research tools and for cancer therapeutics.
-
In Vitro——
-
In Vivo——
-
SynonymsRBC8 | RBC-8 | RBC 8
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorGTPases RalA| GTPases RalB
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number361185-42-4
-
Formula Weight424.45
-
Molecular FormulaC25H20N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 40 mg/mL; 94.24 mM
-
SMILESCOc1ccc(c(c1)C1C(=C(N)Oc2c1c(c1ccc3ccccc3c1)[nH]n2)C#N)OC
-
Chemical Name6-Amino-4-(2,5-dimethoxyphenyl)-1,4-dihydro-3-(2-naphthalenyl)pyrano[2,3-c]pyrazole-5-carbonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yan C, et al. Nature. 2014, 515(7527), 443-447.
molnova catalog
related products
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
Elarofiban TFA
Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
-
BMS-688521
BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.
